Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2012 / N 4

Антикоагулянтная терапия в профилактике и лечении тромбозов: международные рекомендации и реальная клиническая практика (список литературы)
М.В. Котельников

Список литературы 1. Barritt DW, Jordan SC: Anticoagulant drugs in the treatment of pulmonary embolism. Lancet 1960, 1:1309-1312. 2. Goldhaber SZ, Visani L, De Rosa M, for ICOPER. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999;353:1386–9. 3. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000;355:1936–1942. 4. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA1996; 276:811–815. 5. Kakkar V.V., Kakkar S., Sanderson R.M. et al. Efficacy and safety of two regimens of low molecular weight heparin fragment (Fragmin) in preventing postoperative venous thrombolism // Haemostasis. – 1986. – Vol. 16(suppl). – P. 19–24. 6. Quinlan D.J., McQuillan A, Eikelboom JW. Low-molecular weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: meta-analysis of randomized, controlled trials. Ann Intern Med 2004; 140:175-83. 7. Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. Sep 2004;126(3 Suppl):401S-428S. [Medline]. 8. Hirsh J, Guyatt G, Albers GW, et al. Antithrombotic and thrombolytic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(6 suppl):110S- 112S. Available at: http://www.chestnet.org/education/hsp/guidelinesAT8.php. 9. Torbicki A, Perrier A, Konstantinides S, et al; ESC Committee for Practice Guidelines (CPG). Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 29, 2276–2315. 10. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation. 1997;96:61–68. 11. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable 2 angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). Eur Heart J. 1999;20:1553–1562. 12. Wallentin L., Goldstein P., Armstrong P.W., et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction, Circulation 2003; 108: 135- 142. 13. Giraldez R.R., Nicolau J.C., Corbalan R., et al. Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis, Eur Heart J 28 2007 1566-1573. 14. White H.D., Braunwald E., Murphy S.A., et al. Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25, Eur Heart J 28 2007 1066-1071. 15. Murphy SA, Gibson CM, Morrow DA, Van de Werf F, Menown I, Goodman S, Mahaffey K, Cohen M, McCabe C, Antman EM, Braunwald E. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 2007; 28:2077–2086. 16. 2012 ACCF/AHA focused update on the guideline for the management of patients with unstable angina/non-ST elevation myocardial infarction (Updating the 2007 guideline and replacing the 2011 focused update): A report of the ACCF/AHA. Circulation 2012;DOI: 10.1161/CIR0b013e3182566fleo. Available at: http://circ.ahajournals.org/. 17. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal 2011; 32:2999-3054. 18. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With STElevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2009; 54;2205-2241. 19. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal 2012; 33:2569-2619. 20. Yusuf S, Mehta SR. Chrolavicius S et al. 2006. Comparison of fondaparinux and enoxaparin in acute coronary syndromes.N. Engl. J. Med.354(14),1464-1476 (2006). 2 21. Yusuf S, Mehta SR, Chrolavicius S et al. 2006. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA.295(13),1519-1530 (2006). 22. Peters RJ, Joyner C, Bassand JP et al.The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. Eur. HeartJ.29(3),324-331 (2008). 23. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349:1695–702. 24. Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004;140:867–73. 25. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl): 419S-94S. 26. Lassen MR, Bauer KA, Eriksson BI, et al.: Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002, 359:1715-1720. 27. Eriksson BI, Bauer KA, Lassen MR, et al.: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001, 345:1298-1304. 28. Bauer KA, Eriksson BI, Lassen MR, et al.: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001, 345:1305-1310. 29. Turpie AG, Bauer KA, Eriksson BI, et al.: Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hipreplacement surgery: a randomised double-blind trial. Lancet 2002, 359:1721-1726. 30. Bounameaux H, Perneger T: Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention. Lancet 2002, 359:1710-1711. 31. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest. 2012 Feb;141(2 Suppl): 278S-325S. 32. Mega JL, Braunwald E, Wiviott SD, et al.; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. N Engl J Med. January 5, 2012; 366:9-19. 2 33. Reed Miller. Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS. Updated May 24, 2012. www.medscape.com/viewarticle/764433. 34. Patel MR, Mahaffey KW, Garg J, et al. 2011. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891. 35. Emma Hitt. Rivaroxaban vs Warfarin for AFib Causes More GI Bleeding. CHEST 2012: American College of Chest Physicians Annual Meeting. Presented October 22, 2012. http://www.medscape.com/viewarticle/773208?src=mpnews&spon=2. 36. EINSTEIN Investigators; Bauersachs R, Berkowitz SD, Brenner B, et al. Oral Rivaroxaban for Symptomatic Venous Thromboembolism. N Engl J Med 2010; 363:2499-2510. 37. Eriksson BI, Borris LC, Friedman RJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 358, 2765–2775 (2008). 38. Kakkar AK, Brenner B, Dahl OE et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a doubleblind, randomised controlled trial. Lancet 372, 31–39 (2008). 39. Lassen MR, Ageno W, Borris LC et al. Rivaroxaban for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med. 358, 2776–2785 (2008). 40. Turpie AGG, Bauer KA, Davidson B et al. Once-daily oral rivaroxaban compared with subcutaneous enoxaparin every 12 hours for thromboprophylaxis after total knee replacement: RECORD 4. Blood (ASH Annual Meeting Abstracts) 112, 35(2008). 41. Walter Ageno Rivaroxaban for the Prevention of Venous Thromboembolism Following Major Orthopedic Surgery: The RECORD Trials. Expert Rev Cardiovasc Ther. 2009;7(6):569- 576. 42. Cohen A. The Magellan Study Methodology: Rivaroxaban compared with enoxaparin for the prevention of venous thromboembolism in hospitalized medically ill patients. Program and abstracts of the 15th Annual European Hematology Association meeting; June 10-13, 2010; Barcelona, Spain. http://www.medscape.com/viewarticle/757903. 43. Connolly SJ., Ezekowitz MD., Phil. D., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151. 44. Beasley BN, Unger EF, Temple R. Anticoagulant Options – Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran N Engl J Med 2011; 364:1788-1790. 45. Sue Hughes. US Bleeding ADRs Higher With Dabigatran Than Warfarin. Institute of Safe Medication Practices. ISMP Medication Safety Alert, January 12. http://www.medscape.com/viewarticle/756844. 46. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361:2342–52. 2 47. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370:949–956. 48. Eriksson BI, Dahl OE, Rosencher N et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the REMODEL randomized trial. J Thromb Haemost. 2007; 5:2178–85. 49. Ginsberg JS, Davidson BL, Comp PC et al. Oral thrombin inhibitor dabigatran etexilate vs. North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009; 24:1–9. 50. Caprini JA, Hwang E, Hantel S, et al. The oral direct thrombin inhibitor dabigatran etexilate is effective and safe for prevention of major venous thromboembolism following orthopaedic surgery. 2007 Congress of the International Society on Thrombosis and Hemostasis; July 7-13, 2007; Geneva, Switzerland. 51. Eriksson BI, Dahl OE, Huo MH, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011;105:721–729. 52. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012 Mar 12;172(5):397-402. 53. Lewis Krauskopf and Bill Berkrot. Doctors Reserve Judgment on New Blood Clot Drugs. American Heart Association (AHA) 2011 Scientific Sessions. http://www.medscape.com/viewarticle/753621. 2
  

[ Содержание выпуска N 4 | Выпуски журнала | Список журналов ]